

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Pharmadrug Inc. (the "Issuer").

Trading Symbol: BUZZ

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

Please refer to Note 20 of the Company's unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2020 and 2019 for more answers and details to the above questions.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
Jun 15, 2020	Common shares	Exchange on Super Smart Transaction	44,000,000	Deemed price of \$0.05	N/A	Share exchange	Various shareholders	N/A
July 15, 2020	Warrants	Exchange on Super Smart Transaction	35,478,400	Deemed price of \$0.05	N/A	Share exchange	Various shareholders	N/A
Q2 2020	Common shares	Conversion of debentures into units	24,880,000	\$0.05	N/A	Conversion	Various debentures holders	N/A
Q2 2020	Warrants	Conversion of debentures into units, where ½ warrant is attached to each unit	12,440,000	\$0.05	N/A	Conversion	Various debentures holders	N/A

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
May 31, 2020	5,500,000	N/A	Advisory consultants	\$0.11	May 31, 2025	\$0.085

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

The Company is authorized to issue an unlimited number of common shares and preferred shares without par value. The preferred shares may be issued in one or more series and the directors are authorized to fix the number of shares in each series and to determine the designation, rights, privileges, restrictions, and conditions attached to the shares of each series. The Company has not issued any preferred shares to date.

- (b) number and recorded value for shares issued and outstanding,

	Number of common shares	Amount
	#	\$
Balance, December 31, 2019	83,302,274	13,215,765
Issuance on amalgamation transaction	44,000,000	2,860,000
Issuance on conversion of debentures	24,880,000	938,473
Balance, June 30, 2020	152,182,274	17,014,238

- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

The following table summarizes information of stock options outstanding and exercisable as at June 30, 2020:

Date of expiry	Number of options outstanding	Number of options exercisable	Exercise price	Weighted average remaining life
	#		\$	Years
August 16, 2020	1,020,000	1,020,000	0.10	0.13
January 17, 2021	350,000	350,000	0.235	0.55
May 24, 2021	500,000	500,000	0.22	0.90
May 28, 2021	600,000	475,000	0.22	0.91
September 24, 2021	300,000	300,000	0.31	1.24
May 31, 2025	5,500,000	5,500,000	0.11	4.92
	8,270,000	8,145,000	0.14	3.48

The following table summarizes information of warrants outstanding as at June 30, 2020:

Date of expiry	Number of warrants outstanding #	Exercise price \$	Weighted average remaining life Years
August 9, 2020	2,301,873	0.75	0.11
August 9, 2020	78,015	0.49	0.11
August 16, 2020	2,350,000	0.15	0.13
August 16, 2020	467,000	0.10	0.13
January 10, 2021	5,869,159	0.25	0.53
April 17, 2021	813,743	0.22	1.05
May 9, 2021	12,280,912	0.28	1.11
June 12, 2023	15,918,400	0.05	2.95
June 15, 2023	32,000,000	0.05	2.96
	72,079,102	0.13	2.17

(d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

N/A

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Daniel Cohen	Chief Executive Officer, Director
Keith Li	Chief Financial Officer
Harry Resin	Chief Operating Officer
Al Quong	Director
Michael Forbes	Director
Nikolai Vassev	Director
Paul McClory	Director
Robert Schwartz	Director

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated August 28, 2020.

Daniel Cohen
Name of Director or Senior Officer

"Daniel Cohen"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Quarter Ended	Date of Report YY/MM/DD
Pharmadrug Inc.	June 30, 2020	20/08/28
Issuer Address		
77 King Street West, Suite 2905		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Toronto/Ontario/M5K 1H1	()	(647) 202-1824
Contact Name	Contact Position	Contact Telephone No.
Daniel Cohen	CEO	(647) 202-1824
Contact Email Address dcohen@pharmadrug.co	Web Site Address www.pharmadrug.co	